In the CA1, CBD prevented the STZ-induced CB1 downregulation and CB2 upregulation, aligning with studies showing decreased CB1 and increased CB2 expression in postmortem AD brain tissues [83]. This evidence concerns the gene CNR1 and Alzheimer disease.